The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125

[11] Hiissa J(2011)Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases Clin Chem 57 1534-1544

[12] Zhang H(2017)The use of human epididymis 4 and cancer antigen 125 tumor markers in the benign or malignant differential diagnosis of pelvic or adnexal masses Balkan Med J 34 156-162

[13] Xiao X(2016)HE4 multicenter study published to establish HE4 reference value of Chinese healthy population Chin J Clin Oncol 43 280-888

[14] Kirchhoff C(2011)Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases Clin Biochem 44 884-461

[15] Habben I(2016)Level of HE4 is correlated with diagnosis of struma ovarii: a case report Am J Case Rep 17 459-542

[16] Ivell R(2013)Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response Diagn Pathol 8 11-2188

[17] Ruggeri G(2012)Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor PLoS ONE 7 e47672-172

[18] Bandiera E(2014)Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition Reprod Sci 21 538-undefined

[19] Zanotti L(2012)Human epididymis protein 4 (HE4) in benign and malignant diseases Clin Chem Lab Med 50 2181-undefined

[20] Andersen MR(2016)Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer Biomarkers 21 168-undefined

[11] Hiissa J(2011)Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases Clin Chem 57 1534-1544

[12] Zhang H(2017)The use of human epididymis 4 and cancer antigen 125 tumor markers in the benign or malignant differential diagnosis of pelvic or adnexal masses Balkan Med J 34 156-162

[13] Xiao X(2016)HE4 multicenter study published to establish HE4 reference value of Chinese healthy population Chin J Clin Oncol 43 280-888

[14] Kirchhoff C(2011)Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases Clin Biochem 44 884-461

[15] Habben I(2016)Level of HE4 is correlated with diagnosis of struma ovarii: a case report Am J Case Rep 17 459-542

[16] Ivell R(2013)Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response Diagn Pathol 8 11-2188

[17] Ruggeri G(2012)Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor PLoS ONE 7 e47672-172

[18] Bandiera E(2014)Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition Reprod Sci 21 538-undefined

[19] Zanotti L(2012)Human epididymis protein 4 (HE4) in benign and malignant diseases Clin Chem Lab Med 50 2181-undefined

[20] Andersen MR(2016)Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer Biomarkers 21 168-undefined